Indian vaccine maker Bharat Biotech’s nasal COVID-19 vaccine candidate has received regulatory approval for mid-to-late-stage trials on Friday by the government’s ministry of science and technology. A statement from the ministry of science and technology said that the early stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years and the doses were found to be well tolerated. COVAXIN, the company’s COVID-19 vaccine already approved for emergency use approval in the country is administered through an injection.
Renu Swarup, chairperson of the Biotechnology Industry Research Assistance Council, stated, “Bharat Biotech’s BBV154 Covid Vaccine is the first intranasal vaccine being developed in the country entering into a late-stage clinical trial.” Bharat Biotech did not respond immediately to a request for additional details.
